---
title: "HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 1.9 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256983614.md"
datetime: "2025-09-11T20:06:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256983614.md)
  - [en](https://longbridge.com/en/news/256983614.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256983614.md)
---

# HEARTSCIENCES INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 1.9 K

Revenue: As of FY2025 Q1, the actual value is USD 1.9 K.

EPS: As of FY2025 Q1, the actual value is USD -1.58.

### Segment Revenue

-   Revenue: $2,000 for the three months ended July 31, 2025, compared to $0 for the same period in 2024.

### Operational Metrics

-   Net Loss: - $2,054,994 for the three months ended July 31, 2025, compared to - $2,051,689 for the same period in 2024.
-   Gross Margin: $1,140 for the three months ended July 31, 2025, compared to $0 for the same period in 2024.
-   Research and Development Expenses: $997,206 for the three months ended July 31, 2025, compared to $1,224,931 for the same period in 2024.
-   Selling, General and Administrative Expenses: $878,053 for the three months ended July 31, 2025, compared to $850,736 for the same period in 2024.
-   Loss from Operations: - $1,874,119 for the three months ended July 31, 2025, compared to - $2,075,667 for the same period in 2024.
-   Interest Expense: - $183,688 for the three months ended July 31, 2025, compared to - $22,526 for the same period in 2024.
-   Other Income: $2,813 for the three months ended July 31, 2025, compared to $46,504 for the same period in 2024.

### Cash Flow

-   Net Cash Used in Operating Activities: - $1,953,367 for the three months ended July 31, 2025, compared to - $2,018,720 for the same period in 2024.
-   Net Cash Used in Investing Activities: - $814 for the three months ended July 31, 2025, compared to - $833 for the same period in 2024.
-   Net Cash Provided by Financing Activities: $3,648,314 for the three months ended July 31, 2025, compared to $551,683 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue investing in research and development to develop technology for new products and to seek regulatory clearance for the MyoVista wavECG and MyoVista Insights Cloud Platform.
-   **Non-Core Business**: The company is exploring strategic partnerships and additional equity financing to support its operations and growth initiatives.
-   **Priority**: The company aims to achieve FDA clearance for its products and to commercialize its AI-ECG algorithms, with a focus on expanding its market presence and improving its financial performance.

### Related Stocks

- [HSCSW.US](https://longbridge.com/en/quote/HSCSW.US.md)

## Related News & Research

- [Prediction: Vanguard's S&P 500 ETF Will Be Back Above $1 Trillion in Assets Before the Year Is Out. Here's the Math.](https://longbridge.com/en/news/294609950.md)
- [Bitcoin Holders Lose $88,600,000 in Coldcard Crypto Wallet Exploit: Galaxy Researchers](https://longbridge.com/en/news/294653457.md)
- [ROI-OPEC+ oil output hike is irrelevant for now, not for later: Russell](https://longbridge.com/en/news/294620367.md)
- [ANALYSIS-Obesity battle heats up again as Novo claws way back into race with Lilly](https://longbridge.com/en/news/294641770.md)
- [Can Caterpillar (CAT) Justify Its Valuation As AI Data Center Optimism Meets Earnings?](https://longbridge.com/en/news/294635551.md)